AMED Stock - Amedisys, Inc.
Unlock GoAI Insights for AMED
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.35B | $2.24B | $2.22B | $2.21B | $2.07B |
| Gross Profit | $1.02B | $990.87M | $962.77M | $980.76M | $886.15M |
| Gross Margin | 43.3% | 44.3% | 43.3% | 44.3% | 42.8% |
| Operating Income | $94.54M | $156.39M | $180.77M | $251.91M | $219.27M |
| Net Income | $43.23M | $-9,747,000 | $118.61M | $209.07M | $183.61M |
| Net Margin | 1.8% | -0.4% | 5.3% | 9.4% | 8.9% |
| EPS | $1.32 | $-0.30 | $3.65 | $6.41 | $5.64 |
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 29th 2024 | Deutsche Bank | Downgrade | Hold | $101 |
| July 1st 2024 | William Blair | Downgrade | Market Perform | - |
| June 7th 2023 | Truist | Downgrade | Hold | $97 |
| April 21st 2023 | Cantor Fitzgerald | Initiation | Neutral | $87 |
| March 13th 2023 | Barclays | Initiation | Equal Weight | $93 |
| October 27th 2022 | Raymond James | Downgrade | Market Perform | - |
| August 2nd 2022 | UBS | Downgrade | Sell | $95← $145 |
| June 29th 2022 | Stifel | Initiation | Hold | $128 |
| June 21st 2022 | BofA Securities | Downgrade | Underperform | $102← $145 |
Earnings History & Surprises
AMEDEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Jul 29, 2025 | $1.39 | $1.54 | +10.8% | ✓ BEAT |
Q2 2025 | Apr 23, 2025 | $1.13 | $1.25 | +10.6% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $1.05 | $0.96 | -8.6% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $1.17 | $1.00 | -14.5% | ✗ MISS |
Q3 2024 | Jul 24, 2024 | $1.22 | $1.32 | +8.2% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $1.01 | $1.03 | +2.0% | ✓ BEAT |
Q1 2024 | Feb 21, 2024 | $1.03 | $0.94 | -8.7% | ✗ MISS |
Q4 2023 | Oct 24, 2023 | $1.08 | $0.98 | -9.3% | ✗ MISS |
Q3 2023 | Jul 26, 2023 | $1.07 | $1.37 | +28.0% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $0.88 | $1.00 | +13.6% | ✓ BEAT |
Q1 2023 | Feb 15, 2023 | $1.00 | $1.16 | +16.0% | ✓ BEAT |
Q4 2022 | Oct 26, 2022 | $1.24 | $1.15 | -7.3% | ✗ MISS |
Q3 2022 | Jul 27, 2022 | $1.23 | $1.47 | +19.5% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $1.12 | $1.23 | +9.8% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $1.18 | $1.18 | 0.0% | = MET |
Q4 2021 | Nov 2, 2021 | $1.37 | $1.53 | +11.7% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $1.64 | $1.69 | +3.0% | ✓ BEAT |
Q2 2021 | Apr 28, 2021 | $1.43 | $1.54 | +7.7% | ✓ BEAT |
Q1 2021 | Feb 24, 2021 | $1.47 | $1.49 | +1.4% | ✓ BEAT |
Q4 2020 | Oct 28, 2020 | $1.27 | $2.24 | +76.4% | ✓ BEAT |
Frequently Asked Questions about AMED
What is AMED's current stock price?
What is the analyst price target for AMED?
What sector is Amedisys, Inc. in?
What is AMED's market cap?
Does AMED pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AMED for comparison